This is a preview of subscription content, log in via an institution to check access.
Reference
Catt H, et al. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. PharmacoEconomics : 2 Aug 2019. Available from: URL: http://doi.org/10.1007/s40273-019-00826-0
Rights and permissions
About this article
Cite this article
Biosimilar infliximab positive net health benefit for Crohn's disease. PharmacoEcon Outcomes News 835, 8 (2019). https://doi.org/10.1007/s40274-019-6145-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6145-6